IMM Stock Overview A biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImmuPharma plc Competitors Price History & Performance
Summary of share price highs, lows and changes for ImmuPharma Historical stock prices Current Share Price UK£0.052 52 Week High UK£0.074 52 Week Low UK£0.0082 Beta 1.58 1 Month Change 327.28% 3 Month Change 233.98% 1 Year Change 278.18% 3 Year Change -28.18% 5 Year Change -62.04% Change since IPO -90.19%
Recent News & Updates
Is ImmuPharma (LON:IMM) In A Good Position To Deliver On Growth Plans? Jan 25
ImmuPharma plc Announces Breakthrough Findings into Autoimmune Diseases Jan 09
New major risk - Share price stability Jan 07
Immupharma plc Announces Appointment of Ashley Clarke as Company Secretary Dec 04
Immunovia Presents Data from Model Development Study At 2024 AACR Advances in Pancreatic Cancer Medical Conference Sep 17
ImmuPharma plc to Report Q2, 2024 Results on Aug 05, 2024 Jul 29 See more updates
Is ImmuPharma (LON:IMM) In A Good Position To Deliver On Growth Plans? Jan 25
ImmuPharma plc Announces Breakthrough Findings into Autoimmune Diseases Jan 09
New major risk - Share price stability Jan 07
Immupharma plc Announces Appointment of Ashley Clarke as Company Secretary Dec 04
Immunovia Presents Data from Model Development Study At 2024 AACR Advances in Pancreatic Cancer Medical Conference Sep 17
ImmuPharma plc to Report Q2, 2024 Results on Aug 05, 2024 Jul 29
ImmuPharma plc, Annual General Meeting, Jun 28, 2024 Jun 08
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director Apr 30
New minor risk - Financial data availability Mar 18
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm Dec 19
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development Nov 09
No independent directors Oct 12
ImmuPharma plc Announces Changes to Its Board of Directors Aug 12 Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer Detection Jul 13
New major risk - Market cap size Jun 25
ImmuPharma plc, Annual General Meeting, Jun 30, 2023 Jun 06
ImmuPharma plc, Annual General Meeting, May 26, 2023 May 23 ImmuPharma plc Announces Further Positive Progress in Late-Stage Clinical Program in Patients with Chronic Idiopathic Demyelinating Polyneuropathy
Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d test Jan 20
Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US market Jan 18
Price target decreased to UK£0.029 Nov 16
Less than half of directors are independent Nov 16 ImmuPharma plc to Report Q1, 2023 Results on Apr 25, 2023
ImmuPharma plc Appoints Ward Williams Limited as Company Secretary Oct 08
First half 2022 earnings released: UK£0.006 loss per share (vs UK£0.015 loss in 1H 2021) Sep 30
ImmuPharma PLC Provides Update on Lupuzor Jun 28 ImmuPharma plc, Annual General Meeting, Jun 28, 2022
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind May 26
ImmuPharma plc Provides Update on Lupuzor Progress to Phase 3 with Avion May 05
No independent directors Apr 27
ImmuPharma plc Provides Positive Data from Lupuzor/P140 Pharmacokinetic Study Apr 14
ImmuPharma plc Provides an Update on the Lupuzor™ Pharmacokinetic Study, as Part of the New Optimized International Phase 3 Trial of Lupuzor™ in Lupus Patients Feb 08
First half 2021 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in 1H 2020) Oct 03
Less than half of directors are independent Aug 10
Independent Non-Executive Director Stéphane Robert Méry has left the company Aug 05
Senior Independent Non-Executive Director Franco Di Muzio has left the company Aug 05
Co-Founder, President, Chief Scientific Officer & Director D. Henri Zimmer has left the company Jul 02
Shareholders May Be A Bit More Conservative With ImmuPharma plc's (LON:IMM) CEO Compensation For Now Jun 22
Full year 2020 earnings released: UK£0.034 loss per share (vs UK£0.04 loss in FY 2019) May 01
ImmuPharma plc Appoints Ewa Flynn as Company Secretary Jan 19
How Much Is ImmuPharma's (LON:IMM) CEO Getting Paid? Dec 02
ImmuPharma plc Announces Guidance on Forthcoming International Phase 3 Trial of Lupuzor™ in Lupus Patients Nov 20
ImmuPharma plc Announces Update on Submission to the FDA Nov 12
ImmuPharma plc Announces Completion of Analysis from the IMMray and PanCan-d Verification Study Oct 29
First half earnings released Oct 03
Immunovia Announces Positive Results from the IMMray Pancan-D Verification Study Oct 01
ImmuPharma plc announced that it expects to receive £2.35 million in funding from L1 Capital Pty. Limited, The Lind Partners, LLC Sep 23
ImmuPharma plc to Report First Half, 2020 Results on Aug 20, 2020 Aug 14 Shareholder Returns IMM GB Pharmaceuticals GB Market 7D 28.4% 2.9% 2.0% 1Y 278.2% 3.5% 10.8%
See full shareholder returns
Return vs Market: IMM exceeded the UK Market which returned 10.8% over the past year.
Price Volatility Is IMM's price volatile compared to industry and market? IMM volatility IMM Average Weekly Movement 58.0% Pharmaceuticals Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: IMM's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: IMM's weekly volatility has increased from 31% to 58% over the past year.
About the Company ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD.
Show more ImmuPharma plc Fundamentals Summary How do ImmuPharma's earnings and revenue compare to its market cap? IMM fundamental statistics Market cap UK£21.65m Earnings (TTM ) -UK£2.46m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMM income statement (TTM ) Revenue -UK£69.96k Cost of Revenue UK£0 Gross Profit -UK£69.96k Other Expenses UK£2.39m Earnings -UK£2.46m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0059 Gross Margin 100.00% Net Profit Margin 3,519.61% Debt/Equity Ratio 0%
How did IMM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 00:12 End of Day Share Price 2025/01/31 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImmuPharma plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alexander Pye Cavendish null null Cavendish Navid Malik Cavendish Historical (Cenkos Securities)
Show 5 more analysts 
